Gosta Labs, a Helsinki-based health technology company founded by the former Kaiku Health team, has raised €7.5 million in seed funding to accelerate the growth of its AI operating system designed for complex medical fields. The round was led by Voima Ventures, with additional backing from COR Group, the Aho family, and both existing and new supporters, including Reaktor and a network of prominent angel investors. This follows a €1.7 million pre-seed round completed in 2024, bringing total investment to almost €10 million.
Rising complexity in cancer care demands modern AI support
Cancer treatment is becoming markedly more intricate. By 2050, more than 35 million new cases are forecast across over 100 distinct cancer types [1][2]. At the same time, clinicians face several hours of daily administrative work across disparate systems and unstructured clinical information, while multidisciplinary teams must rapidly evaluate an expanding range of personalised treatment choices.
Gosta Labs aims to ease these pressures with an AI-powered operating system tailored to oncology. The platform converts every consultation into structured, high-quality data in real time. It provides clear summaries and visualisations of each patient’s care pathway, automates clinical documentation, and captures structured insights essential for treatment decisions. It also strengthens care quality by reviewing key clinical parameters throughout each treatment pathway and automatically linking clinical decisions to established international guidelines. In doing so, the system supports oncologists in delivering care that is both faster and more consistent.
The AI operating system is already deployed with leading healthcare organisations across Finland, Switzerland, the Baltic region, and Australia.
Early evidence shows gains in oncology workflows
Initial real-world findings from the Gosta AI Operating System were shared at the 2025 ESMO Congress, one of the major global events in oncology. The study indicates that the platform produces high-quality oncology consultation notes aligned with institutional standards in real time, while automatically classifying Performance Status and CTCAE toxicity grades. Oncologists were able to complete follow-up visit documentation in under two minutes on median, significantly lightening the administrative load and allowing more time for direct patient interaction.
“This technology is already reshaping our clinical workflows. The ability to produce structured, accurate notes instantly and classify key clinical parameters automatically frees oncologists to spend their time where it matters most — with their patients. In practice, this has already cut documentation time by over two-thirds for each patient visit at our cancer center”, says Dr. Razvan Popescu, Medical Director at Tumor Center Aargau and the lead investigator in the study.
Founders with a strong digital health pedigree
Established in 2023 by Lauri Sippola and Henri Viertolahti, who previously founded Kaiku Health (acquired by Elekta in 2020), Gosta Labs builds on a proven background in developing and scaling regulated digital-health solutions internationally.
The team brings together AI experts and seasoned oncology and medtech leaders, including Chief Medical Officer Dr. Lionel Hadjadjeba and Chief Operating Officer Reetta Arokoski, both of whom have decades of experience advancing cancer-care technologies worldwide.
“Gosta Labs’ key team members combine proven startup execution, deep domain expertise and top notch AI capabilities. They’ve done it before and know what good looks like, which is an essential for any startup team,” says Jussi Sainiemi, Partner at Voima Ventures. “There’s a lot of hype around AI but Gosta delivers the value it promises and customers love the product.”
“We started Gosta Labs to bring AI to support extremely complex medical specialties like oncology, to give care teams back time and headspace for their patients by taking on the documentation work that drains their day,” says Lauri Sippola, CEO and Co Founder of Gosta Labs. “This funding helps us bring our trusted AI assistant to oncology teams around the world and deepen our medical device grade product and AI foundation, so every patient encounter can be safer, more personal, and less burdened by administration.”